This fund is currently open to new investors as Limited Partners.

This Venture Fund focuses on a novel medical device that revolutionizes cataract surgery worldwide.  With our initial patent pending in America, and a PCT patent process well under way in 147 other countries, Omega Ophthalmics LLC  is poised to alter the cataract landscape.  Cataract surgery is the single most common surgical procedure performed in the United States annually.  Each procedure requires the surgical implantation of an intraocular lens (IOL) for restoration of vision after surgery.  Despite technological advancements in both surgical instrumentation and intraocular lens design, approximately 50% of patients are still unable to see well without glasses after surgery.  We have developed a new, proprietary lens that will increase the number of “glasses free” post-surgery patients to over 90% by reducing the variables during surgery via our proprietary design, revolutionizing a market that has not seen positive, disruptive change in over sixty years. Since the global intraocular lens market has steadily grown and is currently projected to reach $4.3 billion by 2017, our newly developed Omega 3D Intraocular Lens is well positioned to become the new standard lens for cataract surgery.